Immunotherapy with FBTA05 (Bi20), a trifunctional anti-CD3 x anti-CD20 antibody in recurrent childhood B-cell malignancies

被引：0
|
作者：
Schuster, F. [1 ]
Stanglmaier, M. [2 ]
Woessmann, W. [3 ]
Winkler, B.
Meisel, R. [1 ]
Schlegel, P. G. [4 ]
Lindhofer, H. [2 ]
Reiter, A. [3 ]
Borkhardt, A. [1 ]
Buhmann, R. [5 ]
机构：
[1] Dept Paediat Oncol Haematol & Immunol, Dusseldorf, Germany
[2] TRION Res, Munich, Germany
[3] Univ Giessen, Giessen, Germany
[4] Univ Wurzburg, Wurzburg, Germany
[5] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S247 / S247
页数：1
相关论文
共 50 条
  • [1] Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion
    Buhmann, R.
    Simoes, B.
    Stanglmaier, M.
    Yang, T.
    Faltin, M.
    Bund, D.
    Lindhofer, H.
    Kolb, H-J
    BONE MARROW TRANSPLANTATION, 2009, 43 (05) : 383 - 397
  • [2] Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion
    R Buhmann
    B Simoes
    M Stanglmaier
    T Yang
    M Faltin
    D Bund
    H Lindhofer
    H-J Kolb
    Bone Marrow Transplantation, 2009, 43 : 383 - 397
  • [3] IMMUNOTHERAPY OF RECURRENT B-CELL MALIGNANCIES IN ADULT AND PAEDIATRIC PATIENTS WITH FBTA05, A TRIFUNCTIONAL ANTIBODY (ANTI-CD3 X ANTI-CD20) AND ALLOGENEIC DONOR LYMPHOCYTE INFUSION
    Buhmann, R.
    Stanglmaier, M.
    Schuster, F.
    Simoes, B.
    Menzel, H.
    Ruf, P.
    Peschel, C.
    Lindhofer, H.
    Borkhardt, A.
    Kolb, H. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 183 - 183
  • [4] Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies
    Schuster, Friedhelm R.
    Stanglmaier, Michael
    Woessmann, Wilhelm
    Winkler, Beate
    Siepermann, Meinolf
    Meisel, Roland
    Schlegel, Paul G.
    Hess, Juergen
    Lindhofer, Horst
    Borkhardt, Arndt
    Buhmann, Raymund
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (01) : 90 - 102
  • [5] Dissection of GvHD and GvL by FBTA05, a novel trifunctional anti-CD3 x anti-CD20 antibody
    Buhmann, R.
    Stanglmaier, M.
    Simoes, B.
    Menzel, H.
    Peschel, C.
    Ruf, P.
    Lindhofer, H.
    Kolb, H. -J.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S123 - S123
  • [6] Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels
    Stanglmaier, Michael
    Faltin, Margot
    Ruf, Peter
    Bodenhausen, Annette
    Schroeder, Petra
    Lindhofer, Horst
    INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (05) : 1181 - 1189
  • [7] Clinical follow-up of paediatric high-risk patients with recurrent CD20 positive B-cell malignancies treated with the trifunctional antibody FBTA05 (anti-CD3 x anti-CD20)
    Schuster, F.
    Stanglmaier, M.
    Woessman, W.
    Winkler, B.
    Ruf, P.
    Schlegel, P.
    Meisel, R.
    Lindhofer, H.
    Borkhardt, A.
    Buhmann, R.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S456 - S456
  • [8] Adoptive immunotherapy of recurrent B-cell malignancies after allogeneic stem cell transplantation with Bi20 (FBTA05) a CD3xCD20 trifunctional antibody and donor lymphocyte transfusion
    Buhmann, R.
    Simoes, B.
    Stanglmaier, M.
    Yang, T.
    Faltin, M.
    Bund, D.
    Lindhofer, H.
    Kolb, H. -J.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S45 - S45
  • [9] IMMUNOTHERAPY WITH THE TRIFUNCTIONAL ANTIBODY FBTA05 IN PEDIATRIC HIGH RISK PATIENTS WITH RECURRENT CD20 POSITIVE B CELL MALIGNANCIES - A CLINICAL FOLLOW UP
    Buhmann, R.
    Schuster, F.
    Stanglmaier, M.
    Woessmann, W.
    Winkler, B.
    Meisel, R.
    Ruf, P.
    Schlegel, P. G.
    Lindhofer, H.
    Reiter, A.
    Borkhardt, A.
    Buhmann, R.
    HAEMATOLOGICA, 2012, 97 : 479 - 479
  • [10] Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
    Raymund Buhmann
    Stanglmaier Michael
    Hess Juergen
    Lindhofer Horst
    Christian Peschel
    Hans-Jochem Kolb
    Journal of Translational Medicine, 11
12345